The abstract is read at the publisher; the summary is JClub's.
Mechanistic modeling of [177Lu]Lu-PSMA in metastatic castration-resistant prostate cancer identifies a critical activity scale for net tumor control and quantifies efficacy–toxicity trade-offs.
- Why it matters: Clinical [177Lu]Lu-PSMA schedules are still empirically fixed, leaving uncertainty about how tumor response and organ toxicity vary across patients and dosing strategies.
- What they did: The study built a patient-personalizable mathematical model combining tumor growth, radiobiology, and organ-resolved pharmacokinetics from PET uptake and mass data, then ran in silico trials with stochastic virtual patient cohorts.
- The result: In silico trials using cohorts of 500 virtual patients showed consolidated regimens with fewer, higher-activity injections improved overall survival but increased kidney toxicity, with cycle length affecting toxicity and delays beyond 12 weeks reducing efficacy.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.